Mologic in Bedford UK and Maine in the US and Alamar Biosciences in California are partnering on the project.
The collaboration will utilise Alamar’s novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.
Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (COVIOS and COVIGO for personal self-testing) based on its lateral flow assay technology, utilising high affinity, paired antibodies specific for the SARS-CoV-2 nucleoprotein antigen. Read more